Literature DB >> 21153753

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.

Angelica Linnea Quartino1, Lena E Friberg, Mats O Karlsson.   

Abstract

PURPOSE: To improve the predictive capacity of a semi-mechanistic myelosuppression model for neutrophils as the model have shown to over-predict the nadir of neutrophils and, secondly, to develop a model describing the time-course of leukocytes and neutrophils simultaneously. EXPERIMENTAL
DESIGN: The study included 601 cancer patients treated with a 1 h infusion of docetaxel in monotherapy. A total of 3,549 pairwise observations of leukocytes and neutrophils from one treatment cycle were analyzed simultaneously in NONMEM.
RESULTS: A basic model was developed consisting of a neutrophil and a non-neutrophil model, each with the same structure as the semi-mechanistic myelosuppression model. The leukocytes were modeled as the sum of the predicted neutrophils and non-neutrophils. The model described the time-course of the leukocytes well, but was not able to capture the nadir of the neutrophils. Hence the model was further refined and the included modifications (p < 0.001) in the final model are a sigmoid Emax functions for the drug effect, feedback functions on the cell maturation time in bone-marrow and an optimized number of transit compartments for each of the two cell types.
CONCLUSIONS: A joint semi-mechanistic myelosuppression model describing the time-course of leukocytes and neutrophils following docetaxel administration was developed. The data supported a more complex model compared to the previous model developed by Friberg et al. (2002), and increased the model's capacity to accurately describe the time-course of neutrophils following docetaxel therapy. The combined model also illustrates the differences between the cell types and allows prediction of neutrophil counts from leukocyte measurements.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153753     DOI: 10.1007/s10637-010-9603-3

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  41 in total

1.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

2.  PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.

Authors:  A S Zandvliet; W S Siegel-Lakhai; J H Beijnen; W Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; A D R Huitema
Journal:  Clin Pharmacol Ther       Date:  2007-09-12       Impact factor: 6.875

3.  Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.

Authors:  Amelia Ramon-Lopez; Ricardo Nalda-Molina; Belen Valenzuela; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2009-06-02       Impact factor: 4.200

4.  Mechanism-based models for topotecan-induced neutropenia.

Authors:  Frédéric Léger; Walter J Loos; Roland Bugat; Ron H J Mathijssen; Marine Goffinet; Jaap Verweij; Alex Sparreboom; Etienne Chatelut
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

5.  Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

Authors:  Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri H Roché; Jean-Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

6.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.

Authors:  Cristina Segura; Eva Bandrés; Iñaki F Trocóniz; Jesús García-Foncillas; Onintza Sayar; Carmen Dios-Vieítez; Maria Jesús Renedo; María J Garrido
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

8.  Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Authors:  Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.

Authors:  Steven J Kathman; Daphne H Williams; Jeffrey P Hodge; Mohammed Dar
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-29       Impact factor: 3.333

10.  Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.

Authors:  Emma K Hansson; Johan E Wallin; Henrik Lindman; Marie Sandström; Mats O Karlsson; Lena E Friberg
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-14       Impact factor: 3.333

View more
  20 in total

Review 1.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

2.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

3.  Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

Authors:  Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

4.  Transit and lifespan in neutrophil production: implications for drug intervention.

Authors:  Daniel Câmara De Souza; Morgan Craig; Tyler Cassidy; Jun Li; Fahima Nekka; Jacques Bélair; Antony R Humphries
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-13       Impact factor: 2.745

5.  Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.

Authors:  Murad Melhem; Isabelle Delor; Juan Jose Pérez-Ruixo; John Harrold; Andrew Chow; Liviawati Wu; Philippe Jacqmin
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

6.  Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.

Authors:  Shinji Kobuchi; Yukako Ito; Toshiyuki Sakaeda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

7.  Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.

Authors:  Yuri Kheifetz; Moran Elishmereni; Zvia Agur
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-18       Impact factor: 2.745

8.  Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

9.  Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.

Authors:  Quentin Chalret du Rieu; Sylvain Fouliard; Mélanie White-Koning; Ioana Kloos; Etienne Chatelut; Marylore Chenel
Journal:  Invest New Drugs       Date:  2014-05-31       Impact factor: 3.850

10.  Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.

Authors:  Quentin Chalret du Rieu; Sylvain Fouliard; Anne Jacquet-Bescond; Renata Robert; Ioana Kloos; Stéphane Depil; Etienne Chatelut; Marylore Chenel
Journal:  Pharm Res       Date:  2013-06-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.